Background

- The incidence of brain metastases (BM) in breast cancer patients is rising and has become a major clinical challenge.
- So far, limited therapeutic options and insights into the biology of BM exist since only a few studies analyzed exclusively patient data of breast cancer patients.
- In order to increase knowledge about breast cancer patients with BM, our open, multicenter registry was initiated in 2014: The Brain Metastases in Breast Cancer Network Germany (BMBC, GBG79).

Materials and Methods

- Patients with diagnosed BM since 2000 and a history of breast cancer and no history of other malignant or neurological disease can be included in the registry.
- Registration of patient data is allowed retrospectively as well as prospectively into a web-based database ("MedCodes").
- Data of the primary tumor, metastatic disease and BM as well as treatment details are collected.
- For this first analysis, 1004 patients from 92 German centers were included.

Current Status

- 92 participating centers in Germany
- 1004 patients with completed documentation
- 12/2014 start of tissue sample collection for translational research

Results

- Median age at first diagnosis of BM was 56 years (22 – 90).
- 47% of patients (398/848) were HER2 positive, 22% (186/848) were triple-negative and 31% (264/848) had luminal primary tumors indicating a survival of 9.2 months (CI95% 7.8 – 11.2) and patients with 4 or more BM 5.1 months (CI95% 4.0 – 6.2) (p<0.001, Fig.1).
- In patients without surgery and radiotherapy, 88% (496/562) received whole brain radiotherapy, 7% (38/562) stereotactic radiotherapy and 3% received both (14/562) (Table 2).
- One year survival rate from diagnosis of BM was 35.2 % (CI95%: 31.9 – 38.5).

Further Research projects

- So far, this is the largest analysis of breast cancer patients with BM treated in Germany.
- More than three BM were associated with shorter survival compared with three or less BM.
- The recruitment of the registry is ongoing and we aim to include more than 2000 patients by the end of 2016.

Conclusion

- Data of the primary tumor, metastatic disease and BM as well as treatment details are collected.
- This presentation is the intellectual property of the author/presenter. Contact at iwitzel@uke.de for permission to reprint and/or distribute.

Contact

1. German Breast Group:
   - www.germanbreastgroup.de/studien/palliativ/bmbc
   - Email: BrainMet@GermanBreastGroup.de
2. University Medical Center Hamburg-Eppendorf
   - i.witzel@uke.de
   - Prof. Dr. med. Volkmar Mueller v.mueller@uke.de

Cooperation

- San Antonio Breast Cancer Symposium December 8-12, 2015